Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $564.95, for a total transaction of $5,367,025.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,887,819.35. This trade represents a 19.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Price Performance

NASDAQ UTHR traded up $4.63 during trading hours on Monday, reaching $569.57. The company’s stock had a trading volume of 439,733 shares, compared to its average volume of 486,117. The firm has a fifty day simple moving average of $550.17 and a 200-day simple moving average of $501.37. The stock has a market cap of $24.18 billion, a P/E ratio of 21.03, a P/E/G ratio of 1.80 and a beta of 0.60. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the business earned $6.63 EPS. On average, research analysts expect that United Therapeutics Corporation will post 27.4 earnings per share for the current year.

Analyst Ratings Changes

UTHR has been the subject of a number of research reports. Bank of America raised their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. TD Cowen raised their price objective on shares of United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a report on Monday, March 30th. Oppenheimer raised their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. HC Wainwright raised their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Finally, Cantor Fitzgerald raised their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in UTHR. AE Wealth Management LLC grew its position in shares of United Therapeutics by 396.3% during the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after buying an additional 3,424 shares during the period. Great Lakes Advisors LLC grew its position in shares of United Therapeutics by 194.7% during the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after buying an additional 2,975 shares during the period. Optimize Financial Inc acquired a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $444,000. Tobam grew its position in shares of United Therapeutics by 183.9% during the 3rd quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock worth $3,205,000 after buying an additional 4,953 shares during the period. Finally, Perpetual Ltd acquired a new stake in shares of United Therapeutics during the 4th quarter worth approximately $1,059,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.